阿那莫林日本版的价格是多少钱?

The price of Anamorelin

Anamorelin was developed by Ono Pharmaceuticals of Japan and has been launched in Japan in April 2021. However, as of December 20, 2023, it has not been launched in mainland China and is not available in domestic hospital pharmacies. At present, we know that the price of the Japanese version of Anamorelin is about $4,300 per box, and the specification is 50mg*100 capsules, with a 50-day supply.

Purchasing channels for Anamorelin

1. Patients who need Anamorelin can go to Japanese hospital pharmacies to buy it. This method requires long distances and visa application, and the relative cost will also increase. It is not suitable for long-term medication.

2. Patients can also obtain the drugs through the help of domestic professional overseas medical service institutions. This method can mail the drugs to their homes, and the patients can consult online without leaving home. Obtaining the drugs with a doctor's prescription is more cost-effective, can also reduce the financial burden, and is suitable for long-term medication. However, the specific situation is not fixed due to various factors, so you need to consult customer service personnel for specific conditions.

Effects of Anamorelin

Cachexia is common in patients with advanced cancer and manifests as weight loss (mainly lean body mass [LBM]) and anorexia. This study examined the efficacy and safety of the novel selective gastrin receptor agonist anamorelin in Japanese patients with cancer cachexia.

Research Methods

This double-blind clinical trial (ONO-7643-04) enrolled 174 cachectic patients with unresectable stage III/IV non-small cell lung cancer (NSCLC) in Japan. Patients were randomly assigned to daily oral anamorelin (100 mg) or placebo for 12 weeks. The primary endpoint was change from baseline LBM (measured by dual-energy X-ray absorptiometry) over 12 weeks. Secondary endpoints were changes in appetite, weight, quality of life, handgrip strength (HGS), and 6-minute walk test (6MWT) results.

Results

The least squares mean changes (plus and minus standard errors) in LBM from baseline over 12 weeks were 1.38 ± 0.18 kg and -0.17 ± 0.17 kg in the anamorelin and placebo groups, respectively (P < .0001). LBM, weight, and anorexia symptoms were significantly different in both treatment groups compared with baseline at all time points. Anamorelin increased prealbumin at weeks 3 and 9. No changes were found in HGS or 6MWT between the two groups. Twelve-week treatment with anamorelin was safe and well-tolerated in patients with NSCLC.

Conclusion

Anamulin can significantly increase LBM and improve anorexia symptoms and nutritional status in Japanese patients with advanced NSCLC, but it cannot improve motor function. Since there is currently no effective treatment for cancer cachexia, it may be a beneficial treatment option.

The mechanism of action of Anamorelin

Anamolin can activate cannabinoid receptors, thereby improving the patient's appetite and overall health, reducing symptoms such as nausea and vomiting, and improving the patient's quality of life. Activation of the receptors results in the release of substances in the body that are expected to act in the brain to increase appetite and prevent weight loss.

Recommended hot articles:

References

Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018 Feb 1;124(3):606-616. doi: 10.1002/cncr.31128. Epub 2017 Dec 4. PMID: 29205286; PMCID: PMC5814824.